TolerogenixX expands Phase II immune-tolerance trial and closes EUR 12 million Series A financing Ongoing Phase IIb study expands to arm B5-year results of phase I study confirm efficacy and safety of novel immune-tolerance inducing cell therapy in organ transplantationSecond closing of Series A...